There’s a lot to be optimistic about in the Materials sector as 2 analysts just weighed in on Alumis Inc. (ALMS – Research Report) and Martin ...

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...

Alumis (NASDAQ:ALMS – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 12th. Analysts expect the company to announce earnings of ($1.36) ...

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

Oppenheimer lowered the firm’s price target on Alumis (ALMS) to $26 from $32 and keeps an Outperform rating on the shares. The firm says the ...

SOUTH SAN FRANCISCO, Calif. - Alumis Inc. (NASDAQ: ALMS), currently valued at $388 million and trading near its 52-week low of $6.29, and ACELYRIN, INC. (NASDAQ: SLRN) have entered into a definitive ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

Alumis is also developing another tyrosine kinase 2 blocker, A-005, for neuroinflammatory and neurodegenerative conditions ...

H.C. Wainwright analyst Mitchell S. Kapoor revised the price target on Alumis Inc (NASDAQ:ALMS) to $19.00, down from the previous target of $26.00, while retaining a Buy rating for the company's ...

Alumis (ALUM) stock dropped while Acelyrin (SLRN) stock gained in the premarket as the biopharma companies announced an all-stock merger deal. Read more here.